Unknown

Dataset Information

0

Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.


ABSTRACT: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60?mg, Esomeprazole 40?mg, Esomeprazole 20?mg, Pantoprazole 40?mg, Lansoprazole 30?mg, Rabeprazole 20?mg, Omeprazole 20?mg.A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study.For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20?mg, esomeprazole 40?mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30?mg, esomeprazole 40?mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60?mg had significantly more all-cause discontinuation than omeprazole 20?mg [1.54 (1.03-2.29)], pantoprazole 40?mg [1.68 (1.08-2.63)], and lansoprazole 30?mg [1.38 (1.02-1.88)].The standard-dose esomeprazole 40?mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40?mg, pantoprazole 40?mg, esomeprazole 20?mg, and lansoprazole 30?mg showed more benefits in effectiveness and acceptability than other interventions.

SUBMITTER: Li MJ 

PROVIDER: S-EPMC5626283 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2010-01-01 | S-EPMC3108657 | BioStudies
2018-01-01 | S-EPMC6913203 | BioStudies
2015-01-01 | S-EPMC4342326 | BioStudies
1000-01-01 | S-EPMC6046475 | BioStudies
1999-01-01 | S-EPMC28208 | BioStudies
2017-01-01 | S-EPMC5697821 | BioStudies
2016-01-01 | S-EPMC4699636 | BioStudies
2018-01-01 | S-EPMC6330312 | BioStudies
2008-01-01 | S-EPMC6736538 | BioStudies
2015-01-01 | S-EPMC4538514 | BioStudies